Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular E...(y demonstrated using the Lumenis SRT las...),Health

Date:11/5/2009

y demonstrated using the Lumenis SRT laser. By irradiating the fundus with a train of 1.7 micro-second laser pulses it is possible to achieve high peak temperatures around the melanosomes, which leads to a destruction of the RPE, with only a low sub-lethal temperature increase in adjacent tissue structures. This process leads to the multiplication and migration of healthy RPE cells from the periphery which, in turn, help metabolize and improve the overall retina tissue health.

The Lumenis SRT laser was specifically designed to perform selective RPE targeting. This is accomplished by a green (frequency doubled Nd:YLF, 527nm) laser that emits 1.7 microsecond (¼s) pulses at a repetition rate of 100 Hertz (Hz). This low average power, delivered in a train of pulses, confines the laser treatment to the cells containing the target pigment or chromophores, in this case the melanin granules in the RPE cells, thereby achieving selective damage to these particular cells.

About Lumenis:
Lumenis, the world’s largest medical laser company, is a global developer, manufacturer and distributor of laser, light-based and radiofrequency devices for surgical, aesthetic and ophthalmic applications, with more than 800 employees worldwide. Lumenis has over 250 patents, over 75 FDA clearances, an installed base of over 80,000 systems and presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability. Consequently we are able to deliver premium value and service to our customers. Lumenis’ name is derived from Latin meaning “Light of Life”, highlighting the light which is the basis of our technologies used to enhance life. For more information about Lumenis and its products, please go to: www.lumenis.com.

For f
'/>"/>

Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Lumenis(R) Introduces the Newest Innovations in Fractional CO2 Laser Skin Therapy
2. Lumenis Ltd. Announces Senior Leadership Appointments Strengthening the Companys Strategic Businesses
3. Alma Lasers Answers Lumenis Complaint
4. Lumenis(R) Seeks Shareholder Approval of Proposed Class Action Settlement
5. Lumenis Sues Alma Lasers and its 4 founders for 200 Million Shekels
6. Lumenis Announces changes in Lumenis Vision Strategic Business Unit
7. Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting
8. Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA
9. Lumenis(R) Introduces LightSheer(R) Duet(TM) for High Speed Permanent Hair Reduction
10. Lumenis(R) UltraPulse CO2 Laser to be Featured on National Television with Live Pearly Penile Papule (PPP) Procedure
11. Lumenis(R) UltraPulse CO2 Laser to be Featured on National Television with Live Pearly Penile Papules (PPP) Procedure